Guggenheim Issues Positive Forecast for Revolution Medicines (NASDAQ:RVMD) Stock Price

Revolution Medicines (NASDAQ:RVMD) had its price objective hoisted by analysts at Guggenheim from $240.00 to $275.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Guggenheim’s target price indicates a potential upside of 24.35% from the company’s previous close.

Several other research analysts have also issued reports on the company. Raymond James Financial restated a “strong-buy” rating and issued a $248.00 price target on shares of Revolution Medicines in a research report on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Revolution Medicines in a research note on Friday, July 17th. TD Cowen upgraded Revolution Medicines to a “strong-buy” rating in a report on Monday. Wedbush boosted their target price on Revolution Medicines from $201.00 to $225.00 and gave the stock an “outperform” rating in a research report on Thursday. Finally, Sanford C. Bernstein upped their price target on Revolution Medicines from $151.00 to $179.00 and gave the company a “market perform” rating in a research note on Friday, August 21st. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $195.22.

Revolution Medicines Stock Performance

Revolution Medicines stock opened at $221.15 on Friday. Revolution Medicines has a 1 year low of $37.56 and a 1 year high of $224.31. The company’s 50-day moving average is $192.43 and its two-hundred day moving average is $148.17. The company has a current ratio of 11.38, a quick ratio of 11.38 and a debt-to-equity ratio of 0.40. The company has a market cap of $47.40 billion, a PE ratio of -25.07 and a beta of 1.39.

Revolution Medicines (NASDAQ:RVMD) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($3.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.04) by ($1.02). During the same quarter in the previous year, the company earned ($1.31) EPS. Equities analysts anticipate that Revolution Medicines will post -8.82 earnings per share for the current year.

Insider Buying and Selling

In other Revolution Medicines news, insider Stephen Michael Kelsey sold 4,175 shares of the business’s stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $156.12, for a total value of $651,801.00. Following the completion of the transaction, the insider directly owned 291,876 shares of the company’s stock, valued at approximately $45,567,681.12. The trade was a 1.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Mark A. Goldsmith sold 80,000 shares of the firm’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $209.20, for a total value of $16,736,000.00. Following the sale, the insider directly owned 267,330 shares in the company, valued at approximately $55,925,436. This represents a 23.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 212,497 shares of company stock worth $38,206,486 over the last ninety days. Insiders own 7.60% of the company’s stock.

Institutional Investors Weigh In On Revolution Medicines

Large investors have recently made changes to their positions in the stock. Corient Private Wealth LP boosted its stake in Revolution Medicines by 5.9% in the 2nd quarter. Corient Private Wealth LP now owns 10,537 shares of the company’s stock worth $1,973,000 after purchasing an additional 583 shares during the period. HighTower Advisors LLC lifted its holdings in shares of Revolution Medicines by 311.2% in the second quarter. HighTower Advisors LLC now owns 10,485 shares of the company’s stock valued at $1,964,000 after purchasing an additional 7,935 shares in the last quarter. California State Teachers Retirement System lifted its holdings in shares of Revolution Medicines by 26,920.9% in the second quarter. California State Teachers Retirement System now owns 44,659,351 shares of the company’s stock valued at $8,363,803,000 after purchasing an additional 44,494,074 shares in the last quarter. Washington Trust Advisors Inc. acquired a new position in shares of Revolution Medicines during the second quarter worth about $90,000. Finally, Readystate Asset Management LP boosted its position in shares of Revolution Medicines by 18.5% during the second quarter. Readystate Asset Management LP now owns 37,727 shares of the company’s stock worth $7,066,000 after buying an additional 5,880 shares during the period. Institutional investors own 94.34% of the company’s stock.

Key Revolution Medicines News

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: FDA approval creates a major commercial catalyst. RASONQUE is described as the first broad RAS-targeted medicine approved for metastatic pancreatic cancer, potentially establishing a new treatment option for patients with limited alternatives. FDA approval announcement
• Positive Sentiment: Analysts remain bullish after the approval. HC Wainwright reiterated a “Buy” rating and a $280 price target, above the referenced $221.15 price, while forecasting a narrower FY2027 loss of $6.86 per share. Truist also raised its target to $239 and Wedbush increased its target to $225, both maintaining positive ratings.
• Positive Sentiment: Early launch expectations are favorable. RBC reportedly views the RASONQUE launch as capable of moving quickly, while Oppenheimer said the product’s label expands Revolution Medicines’ commercial opportunity. The company’s decision to remain independent could allow shareholders to retain greater value from the drug’s potential.
• Neutral Sentiment: Near-term financial results will still reflect a development-stage business. HC Wainwright projects quarterly 2027 losses of $2.06, $1.70, $1.62 and $1.47 per share, for a full-year loss of $6.86 per share. Investors are likely to focus on prescription trends, reimbursement and initial revenue after the launch.
• Negative Sentiment: RASONQUE’s $39,800 monthly price may create access and reimbursement risks. Although the price supports substantial revenue potential, it could attract scrutiny from payers and policymakers or slow patient access, tempering some of the enthusiasm surrounding the FDA decision. RASONQUE pricing article

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.